retatrutide phase 2 study results Safety, Side Effects & Provider Use 🚨 Retatrutide Phase 2 is

Patients should be aware that tirzepatide may reduce the effectiveness of oral contraceptives, particularly after initiation and dose increases

Semaglutide Injection (Wegovy) for weight loss is now under review, following the authorization application submitted in June 2023

Retatrutide is a triple-hormone receptor agonist from Eli Lilly that produced 2428% average weight loss in Phase 2 trials, significantly exceeding the 1215% typical of semaglutide and the 1522% of tirzepatide

However, if the medication was frozen or exposed to excessive heat, it should be discarded immediately as potency cannot be guaranteed

Lantus from Sanofi is losing market share to Lilly and their insulin glargine analog (Basaglar)